Table 1 Baseline characteristics of included breast cancer patients (n = 300)
|  | White (n = 91) 30.3% | Black (n = 209) 69.7% | All Patients (n = 300) 100% | p-Value |
|---|---|---|---|---|
Age | ||||
  ≤ 39 | 2 (2.2%) | 6 (2.9%) | 8 (2.7%) | 0.074 |
 40–59 | 16 (17.6%) | 62 (29.7%) | 78 (26.0%) |  |
 60–79 | 51 (56.0%) | 110 (52.6%) | 161 (53.7%) |  |
  ≥ 80 | 22 (24.2%) | 31 (14.8%) | 53 (17.7%) |  |
BMI | ||||
 Normal | 15 (16.5%) | 29 (13.9%) | 44 (14.7%) | 0.058 |
 Overweight | 36 (39.6%) | 54 (25.8%) | 90 (30.0%) |  |
 Obese | 30 (33.0%) | 90 (43.1%) | 120 (40.0%) |  |
 Morbidity | 10 (11.0%) | 36 (17.2%) | 46 (15.3%) |  |
Grade | ||||
 I | 29 (32.2%) | 40 (19.1%) | 69 (23.0%) | 0.035 |
 II | 32 (35.6%) | 75 (35.9%) | 107 (35.7%) |  |
 III- IV | 30 (33.0%) | 94 (45.0%) | 124 (41.3%) |  |
ER status | ||||
 Positive | 68 (74.7%) | 137 (65.6%) | 205 (68.3%) | 0.004 |
 Negative | 20 (22.0%) | 72 (34.4%) | 92 (30.7%) |  |
 Unknown | 3 (3.3%) | 0 (0.0%) | 3 (1.0%) |  |
PR status | ||||
 Positive | 59 (64.8%) | 101 (48.3%) | 160 (53.3%) | 0.015 |
 Negative | 30 (33.0%) | 106 (50.7%) | 136 (45.3%) |  |
 Unknown | 2 (2.2%) | 2 (1.0%) | 4 (1.3%) |  |
HER2 status | ||||
 Positive | 26 (28.6%) | 35 (16.7%) | 61 (20.3%) | 0.053 |
 Negative | 62 (68.1%) | 169 (80.9%) | 231 (77.0%) |  |
 Unknown | 3 (3.3%) | 5 (2.4%) | 8 (2.7%) |  |
7th AJCC TNM stage | ||||
 Stage IA | 42 (46.2%) | 60 (28.7%) | 102 (34.0%) | 0.043 |
 Stage IIA | 15 (16.5%) | 54 (25.8%) | 69 (23.0%) |  |
 Stage IIB | 9 (9.9%) | 36 (17.2%) | 45 (15.0%) |  |
 Stage IIIA | 7 (7.7%) | 20 (9.6%) | 27 (9.0%) |  |
 Stage IIIB | 11 (12.1%) | 17 (8.1%) | 28 (9.3%) |  |
 Stage IIIC | 3 (3.3%) | 14 (6.7%) | 17 (5.7%) |  |
 Stage IV | 4 (4.4%) | 8 (3.8%) | 12 (4.0%) |  |
8th AJCC TNM stage | ||||
 Stage IA | 25 (27.5%) | 38 (18.2%) | 63 (21.0%) | 0.011 |
 Stage IB | 23 (25.3%) | 35 (16.7%) | 58 (19.3%) |  |
 Stage IIA | 8 (8.8%) | 24 (11.5%) | 32 (10.7%) |  |
 Stage IIB | 9 (9.9%) | 12 (5.7%) | 21 (7.0%) |  |
 Stage IIIA | 4 (4.4%) | 30 (14.4%) | 34 (11.3%) |  |
 Stage IIIB | 3 (3.3%) | 26 (12.4%) | 29 (9.7%) |  |
 Stage IIIC | 14 (15.4%) | 35 (16.7%) | 49 (16.3%) |  |
 Stage IV | 5 (5.5%) | 9 (4.3%) | 14 (4.7%) |  |